VanEck Biotech ETF (NASDAQ:BBH) Sees Large Growth in Short Interest

VanEck Biotech ETF (NASDAQ:BBH) was the target of a large growth in short interest in July. As of July 31st, there was short interest totaling 21,232 shares, a growth of 110.7% from the July 15th total of 10,079 shares. Currently, 1.1% of the company’s stock are sold short. Based on an average daily volume of 5,392 shares, the days-to-cover ratio is currently 3.9 days.

Insider Buying and Selling at VanEck Biotech ETF

In related news, major shareholder Sardar Biglari sold 6,533 shares of VanEck Biotech ETF stock in a transaction on Wednesday, July 15th. The shares were sold at an average price of $16.71, for a total value of $109,166.43. Following the completion of the sale, the insider owned 3,552,710 shares of the company’s stock, valued at approximately $59,365,784.10. The trade was a 0.18% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last quarter, insiders have sold 10,493 shares of company stock worth $175,335.

Institutional Trading of VanEck Biotech ETF

A number of institutional investors and hedge funds have recently modified their holdings of BBH. Empowered Funds LLC bought a new position in VanEck Biotech ETF in the 4th quarter worth $38,000. Allworth Financial LP boosted its holdings in VanEck Biotech ETF by 255.0% during the fourth quarter. Allworth Financial LP now owns 426 shares of the company’s stock valued at $81,000 after acquiring an additional 306 shares during the period. Fifth Third Bancorp bought a new stake in VanEck Biotech ETF during the first quarter valued at about $127,000. Huntington National Bank acquired a new stake in shares of VanEck Biotech ETF in the fourth quarter valued at about $132,000. Finally, Evelyn Partners Asset Management Ltd grew its position in shares of VanEck Biotech ETF by 16.9% in the fourth quarter. Evelyn Partners Asset Management Ltd now owns 941 shares of the company’s stock valued at $178,000 after purchasing an additional 136 shares during the last quarter. 32.05% of the stock is currently owned by institutional investors and hedge funds.

VanEck Biotech ETF Stock Down 0.1%

Shares of VanEck Biotech ETF stock opened at $217.92 on Monday. The stock has a 50 day moving average price of $202.89 and a two-hundred day moving average price of $194.31. VanEck Biotech ETF has a 12-month low of $160.91 and a 12-month high of $221.11.

About VanEck Biotech ETF

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.